4.6 Article

Strategic Transformation of Population Studies: Recommendations of the Working Group on Epidemiology and Population Sciences From the National Heart, Lung, and Blood Advisory Council and Board of External Experts

Journal

AMERICAN JOURNAL OF EPIDEMIOLOGY
Volume 181, Issue 6, Pages 363-368

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/aje/kwv011

Keywords

big data; clinical trials; cohort studies; epidemiology; public health; training

Funding

  1. Zoll Lifecor
  2. Johnson Johnson
  3. Boehringer Ingelheim
  4. Bristol Myers Squibb
  5. Pfizer
  6. Gilead Sciences
  7. GlaxoSmithKline
  8. Eli Lilly
  9. Medicine's Company
  10. Astra Zeneca
  11. Daiichi Sankyo
  12. Janssen Pharmaceuticals
  13. Salix Pharmaceuticals
  14. Bayer
  15. Hoffmann-La Roche
  16. Armetheon
  17. Medtronic Foundation
  18. Merck Co.
  19. Sanofi-Aventis
  20. Takeda

Ask authors/readers for more resources

In 2013, the National Heart, Lung, and Blood Institute assembled a working group on epidemiology and population sciences from its Advisory Council and Board of External Experts. The working group was charged with making recommendations to the National Heart, Lung, and Blood Advisory Council about how the National Heart, Lung, and Blood Institute could take advantage of new scientific opportunities and delineate future directions for the epidemiology of heart, lung, blood, and sleep diseases. Seven actionable recommendations were proposed for consideration. The themes included 1) defining the compelling scientific questions and challenges in population sciences and epidemiology of heart, lung, blood, and sleep diseases; 2) developing methods and training mechanisms to integrate big data science into the practice of epidemiology; 3) creating a cohort consortium and inventory of major studies to optimize the efficient use of data and specimens; and 4) fostering a more open, competitive approach to evaluating large-scale longitudinal epidemiology and population studies. By building on the track record of success of the heart, lung, blood, and sleep cohorts to leverage new data science opportunities and encourage broad research and training partnerships, these recommendations lay a strong foundation for the transformation of heart, lung, blood, and sleep epidemiology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available